<DOC>
	<DOCNO>NCT01741194</DOCNO>
	<brief_summary>This study evaluate effect daily dose AC-1204 cognition , activity daily live , resource utilization , quality life , pharmacokinetic measure safety among participant mild moderate Alzheimer 's Disease .</brief_summary>
	<brief_title>AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Dementia status mild moderate CT MRI scan within 18 month prior screen compatible diagnosis probable Alzheimer 's disease Score Wechsler Memory Scale Logical Memory II recall predetermine cutoff , adjust education level Confirmed apolipoprotein E genotype prior randomization Prior current use medication corresponds protocol requirement Stable medical condition , exception dementia , least 3 consecutive month prior screen No active suicidal thought within 6 month screen , active history suicide attempt previous 2 year , 1 lifetime suicide attempt , serious suicidal risk Able comply protocol test procedure duration study Has permanent caregiver ( caregiver expect change course study ) willing attend visit , oversee participant 's compliance protocol procedure study medication administration , report participant 's status Resides community ( include assist living facility , exclude longterm care nursing facility ) Both participant caregiver ability read write English Spanish hearing , vision physical ability adequate perform assessment ( corrective aid allow ) Participant caregiver provide full write informed consent prior performance protocolspecified procedure . If participant unable provide inform consent due cognitive status , provision inform consent cognitively intact legally acceptable representative ( accordance local law , regulation ethic committee policy ) Participant able ingest oral medication Current use , use within 3 month baseline , mediumchain triglyceridecontaining product Use investigational agent within 60 day prior screen Known allergy hypersensitivity milk soy product In opinion investigator , presence history advance , severe , progressive unstable disease type could interfere protocol assessment put participant particular risk Any medical neurological condition Alzheimer 's disease could explain patient 's dementia History clinical laboratory evidence moderate congestive heart failure Clinically significant ECG abnormality screen History new cardiovascular event within 6 month prior baseline History current psychiatric illness Major depression determine Cornell Scale Depression Dementia Insulindependent diabetic Systolic blood pressure &gt; 165 mmHg diastolic blood pressure &gt; 95 mmHg Drop 20 mm Hg systolic blood pressure great upon stand upright seat position within 3 minute screen Clinically significant anemia screen Clinically significant renal disease insufficiency screen Laboratory value liver function test &gt; 2.5 time upper limit normal screen history severe liver disease Fasting triglycerides &gt; 2.5 time upper limit normal screen Clinically significant B12 deficiency within 12 month prior screen Inflammatory bowel disease peptic ulcer disease . Participants current history ( within last 5 year ) complicate reflux disease severe GERD wellcontrolled medication . Irritable bowel syndrome , diverticular disease ( e.g. , diverticulosis diverticulitis ) , chronic gastritis ( exclusionary diagnosis acute event within 5 year prior Screening . ) Has donate â‰¥ 2 unit blood within 2 month prior screen History alcohol drug abuse within 6 month prior screen , positive urine drug test screening Participant caregiver immediate family member employee clinical site , sponsor sponsor 's agent An alternative cause dementia Alzheimer 's disease determine require CT MRI scan within 18 month prior screen History neoplasm malignancy within 5 year prior screen , except basal cell squamous cell carcinoma skin Clinically significant hypothyroidism determine thyroid function test screen Participant schedule expect hospitalization and/or surgery course study</criteria>
	<gender>All</gender>
	<minimum_age>66 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>